[Tanshinone IIA down-regulates the expression of MMP-12 and TF in RAW 264.7 cells]

Yan Wang1, Zhi-Yuan Fang, Shi-An Huang

  • 1Second Department of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 514001, China. wy6806003@ 163.com

Abstract

Insights

Tanshinone IIA (TanIIA) effectively inhibits cell proliferation and reduces tissue factor (TF) and matrix metalloproteinase-12 (MMP-12) in macrophages. These beneficial effects are linked to TanIIA's potent antioxidant properties.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Oxidative Stress Research

Background:

  • Oxidized low-density lipoprotein (ox-LDL) can induce inflammation in macrophages.
  • Tissue factor (TF) and matrix metalloproteinase-12 (MMP-12) are implicated in cardiovascular disease pathogenesis.
  • RAW264.7 cells are a common model for studying macrophage responses.

Purpose of the Study:

  • To evaluate the impact of tanshinone IIA (TanIIA) on TF and MMP-12 expression in ox-LDL-stimulated RAW264.7 cells.
  • To investigate the underlying mechanisms, particularly the role of antioxidant activity.

Main Methods:

  • RAW264.7 cells were treated with ox-LDL and varying concentrations of TanIIA.
  • Cell proliferation was measured using MTT assay.
  • Superoxide dismutase (SOD) activity, malondialdehyde (MDA), TF levels, and MMP-12 expression were quantified.

Main Results:

  • TanIIA demonstrated dose-dependent inhibition of cell proliferation.
  • Significant increases in SOD activity were observed.
  • Decreased levels of MDA, TF, and MMP-12 expression were noted following TanIIA treatment.

Conclusions:

  • TanIIA suppresses ox-LDL-induced proliferation, TF, and MMP-12 expression in RAW264.7 cells.
  • The observed effects are likely mediated by the antioxidant capacity of TanIIA.
  • TanIIA presents a potential therapeutic agent for conditions involving macrophage-mediated inflammation.